Tecen­triq pass­es neoad­ju­vant breast can­cer tri­al as Roche looks for ear­ly start on the next big check­point op­por­tu­ni­ty

Shot through hun­dreds of tri­als over the last decade, check­point in­hibitors have proven a ver­sa­tile tool. First ap­proved for melanoma, col­lec­tive­ly they now cov­er dozens …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER